timothy sykes logo

Stock News

SciSparc Shares Surge: Time to Invest?

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 9/30/2025, 9:19 am ET 9/30/2025, 9:19 am ET | 6 min 6 min read
SciSparc Shares Surge: Time to Invest? Thumbnail

SciSparc Ltd. stocks have been trading up by 31.84 percent driven by positive market sentiment from recent developments.

  • The stock experienced a whopping 124% premarket surge following a positive legal ruling. The Jerusalem District Court granted a temporary halt on the merger proceedings with AutoMax until Sep 30, stirring optimism among investors.

  • The approval of the N2OFF stockholders to acquire MitoCareX Bio Ltd. places SciSparc in a robust position to integrate cutting-edge cancer treatments.

  • Plans to revolutionize AI drug discovery through quantum computing-driven 3D modeling for central nervous system disorders have sparked a 26% stock increase, bolstering investor confidence.

Candlestick Chart

Live Update At 09:19:00 EST: On Tuesday, September 30, 2025 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 31.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Metrics and Market Impact

Many traders make the mistake of seeking quick wins, only to find themselves at a loss. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This mindset encourages traders to prioritize consistent profitability over gambling on major swings, ultimately leading to more sustainable trading success.

Stock charts for SciSparc have been displaying roller-coaster-like fluctuations, mirroring the volatility often seen with companies championing groundbreaking tech advancements. For instance, SciSparc’s stock opened at $4.49 on Sep 29th, 2025, before closing slightly down at $4.46. Despite this minor dip, previous data reveals significant increases on days when major announcements were made, such as the $6.09 close on Sep 25th, marking a substantial climb from the $3.83 close on the preceding day, reflecting investor eagerness.

From a broader financial standpoint, SciSparc’s recent earnings shed light on valuable insights. With a revenue metrics of approximately $1.31M, and an enterprise value of $694,138, the company positions itself with a price-to-sales ratio of 1.75. These figures suggest that the financial landscape within SciSparc is largely reflective of potential epic growth, fueled primarily by its ventures into quantum computing and drug modeling endeavors.

In light of their key ratios, SciSparc displays a book value per share (BVPS) at $13.74, yet their return on invested capital (ROIC) over the last year stands at a glaring negative -81.96, emphasizing the inherent risk and uncertainty linked with rapid innovation in the biotech sphere. The debt-to-equity ratio is absent, indicating allocation toward innovative endeavors over financial stabilization, given the stakes involving unproven, transformative technologies.

Financial documents highlight total assets of $10.35M with liabilities summing up to $1.41M. These figures further outline a company pouring resources into aggressive expansion, driven by scientific innovations like AI-based protein modeling programs. The potential gains from such ventures could dramatically sway their financial standing.

The integration of MitoCareX has broader implications for SciSparc’s growth. This strategic acquisition allows SciSparc to bridge their innovative drug discovery platforms with MitoCareX’s specialized treatments targeting resistant cancers, potentially yielding blockbuster advancements in medical treatment capacities while expanding financial prospects due to synergistic intellectual property assimilation.

Impact of News and Stock Sentiment

In a sweeping turn of events, SciSparc’s stock witnessed a stark surge as announcements of its initiative out into quantum computing to advance drug modeling hit the market. This promising technological leap drew serious attention, as it propels SciSparc into the untapped echelons of futuristic medicine, challenging the norm and shaking traditional pharmaceutical ground.

The temporary stay granted by the Jerusalem District Court provided investors with a sigh of relief. It brought positive speculation back into the narrative, especially as the news coincided with stakeholders’ approval of acquiring MitoCareX Bio Ltd. This favorable legal decision, when amalgamated with strategic mergers, augments SciSparc’s growth trajectory, providing formidable grounds for elevating stock values to new heights.

Quantum computing in drug discovery remains a burgeoning realm, presenting SciSparc as an adventurous forerunner poised to disrupt age-old methodologies. As such transformative tech becomes intertwined within SciSparc’s processes, the investor community’s reaction remains affirmative, albeit with reminders of the speculative nature paralleling such fresh, innovative pursuits.

More Breaking News

Exploring Future Prospects

Drawing parallels to those gold rush days, SciSparc’s newfound journey into AI-driven drug modeling and its entanglement with quantum computing open doors to indispensable opportunities, albeit laden with risks synonymous with exploratory medical ventures. Prospects involving central nervous system treatments position SciSparc on a precipice of reshaping healthcare, potentially unlocking substantial value and transformative possibilities.

Moreover, albeit at different magnitudes, integrating cancer treatment lines through MitoCareX significantly amplifies this potential. By entwining their developmental arm with proven cancer mitigation ventures, SciSparc extends its portfolio towards addressing intricate medical challenges, thereby adding layers of future protective shields against the typical setbacks of single-industry dependencies.

For traders, the landscape has changed, presenting both the gamble and the glitter of significant paybacks. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” The financial uplift observed following innovative announcements conveys that SciSparc’s trajectory, albeit volatile, has captured market intrigue and speculative bullishness. With the stirring meld of legal reliefs, acquisitions, and technological ventures, SciSparc lays the groundwork for potential sector-defining strides.

This discourse interleaves industry possibilities with financial realities, highlighting the compelling yet caution-filled nature of engaging with companies like SciSparc that dance at the crossroads of cutting-edge innovation and uncharted progenies in biotechnological advancement.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”